ArticleBMC cancer2025
Quantification of intratumoral heterogeneity using habitat-based MRI radiomics for predicting high-Gleason scores and castration-resistant PCa: retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal radiomics incorporating intratumoral heterogeneity for prognostic assessment of metastatic outcomes in invasive breast cancer.Breast cancer research : BCR · 2026Article
- Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeProstate cancer (PCa) with high-Gleason Scores (GS) tends to have aggressive clinicopathological characteristics and a poor prognosis. we aimed to develop and validate an MRI-based habitat imaging (HI) model for the preoperative prediction of high-GS and castration-resistant prostate cancer (CRPC). METHODS AND MATERIALS: We collected T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images from 264 prostate cancer patients.Task 1 involved distinguishing between high and low GS PCa, followed by Task 2 which aimed to predict the development of CRPC in high-GS PCa cases. Task 1 extracted whole-tumor radiomic features and tumor microenvironment heterogeneity-based radiomic features from MRI images of 264 patients to construct a radiomic signature and an intratumoral heterogeneity (ITH) signature. Multivariate logistic regression analysis was employed to identify significant independent clinical predictive variables, which were then integrated with the radiomic and ITH signatures to develop a combined model. In Task 2, whole-tumor and tumor microenvironment heterogeneity-based radiomic features were extracted from MRI images of 142 high-GS patients to build an intratumoral heterogeneity signature. The discriminatory performance of these features was evaluated through receiver operating characteristic (ROC) curve analysis, while subsequent decision curve analysis (DCA) was conducted to assess the clinical utility value of the radiomics features.
resultsIn Task 1, the cohort of 264 patients was randomly split into a training set (n=184) and a validation set (n=80), corresponding to a ratio of 7:3. The ITH model demonstrated superior performance over the Radiomics model in both the training and test sets, with AUC values of 0.892 and 0.826, respectively, for predicting high-GS PCa. The combined model achieved even better performance, yielding AUCs of 0.900 and 0.832 in the training and test sets. In Task 2, among the 169 enrolled cases with GS ≥ 4+3, 142 were successfully followed up, of which 25 developed CRPC within one year after ADT. The ITH model constructed for this task achieved optimal AUC values of 0.802 and 0.840 in the training and test sets, respectively.
conclusionsOur study developed ITH signatures that quantified ITH using habitat-based MRI radiomics, which demonstrated outstanding performance in predicting both high GS and CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.